Winkelmann, Michael
Blumenberg, Viktoria
Rejeski, Kai
Quell, Christina
Bücklein, Veit L.
Ingenerf, Maria
Unterrainer, Marcus
Schmidt, Christian
Dekorsy, Franziska J.
Bartenstein, Peter
Ricke, Jens
von Bergwelt-Baildon, Michael
Subklewe, Marion
Kunz, Wolfgang G.
Funding for this research was provided by:
the Bavarian Cancer Research Center
Else Kröner-Fresenius-Stiftung
Deutschen Konsortium für Translationale Krebsforschung
Medical Faculty LMU, "FöFoLe" (1147)
Article History
Received: 28 June 2023
Accepted: 10 October 2023
First Online: 20 October 2023
Declarations
:
: All medical records and imaging studies were reviewed with the approval of the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 19–817).
: Informed consent was obtained from all individual participants included in the study.
: V.B.: BMS/Celgene: research funding; Kite/Gilead: consultancy, honoraria, research funding; Janssen: research funding, honoraria; Novartis: research funding, honoraria; Roche: consultancy, research funding; Takeda: research funding. K.R.: Kite/Gilead: research funding; Kite/Gilead: travel support; Novartis: honoraria. V.L.B.: Amgen: honoraria; Celgene/BMS: research funding; Kite/Gilead: research funding, honoraria; Novartis: honoraria; Pfizer: honoraria. C.S.: Kite/Gilead: travel support. M.v.B.: Astellas: consultancy, research funding, and honoraria; BMS: consultancy, research funding, and honoraria; Kite/Gilead: consultancy, research funding, and honoraria; Miltenyi: consultancy, research funding, and honoraria; Mologen: consultancy, research funding, and honoraria; MSD Sharp & Dohme: consultancy, research funding, and honoraria; Novartis: consultancy, research funding, and honoraria; Roche: consultancy, research funding, and honoraria. M.S.: Amgen: research funding, speakers bureau; Astra Zeneca: speakers bureau; Aven Cell: consultancy; BMS/Celgene: research funding, speakers bureau; CDR-Life: consultancy; Gilead: research funding, speakers bureau; GSK: speakers bureau; Ichnos Sciences: consultancy; Incyte Biosciences: consultancy; Janssen: research funding, consultancy, speakers bureau; Miltenyi Biotec: research funding, consultancy; Morphosys: research funding; Molecular Partners: consultancy; Novartis: research funding, consultancy, speakers bureau; Pfizer: consultancy, speakers bureau; Roche: research funding, speakers bureau; Seattle Genetics: research funding; Takeda: research funding, consultancy, speakers bureau. W.G.K.: Bristol Myers Squibb: advisor; mint Medical: advisor; Need, Inc: advisor; Boehringer Ingelheim, advisor. The remaining authors declare no competing financial interests. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.